We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document contains a synopsis of causation occurring in irritable bowel syndrome.
Latest data from the UK Health Security Agency (UKHSA) on scarlet fever and invasive group A streptococcus cases.
Cultural validation of the Patient Health Questionnaire was carried out in 306 adults attending primary care facilities in small towns
Blue Badge parking for people with disabilities: who can get a badge and how to apply.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
This PAR covers the assessment of the proposal to make Buscopan IBS Relief, Hyoscine Butylbromide 10mg tablets available through general retail outlets.
An annual publication providing statistics on restricted patients in England and Wales
Atnahs Pharma UK Ltd has informed the MHRA that the batches of Clobazam Atnahs 5mg/5ml and 10mg/5ml Oral Suspension listed in this notification do not contain the most up to date safety information.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.